Skip to content

Biomarkers for fatigue in patients with Myasthenia Gravis

Biomarkers for fatigue in patients with Myasthenia Gravis - Biomarkers for fatigue in Myasthenia Gravis

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON55325
Enrollment
115
Registered
2021-07-05
Start date
2022-05-19
Completion date
Unknown
Last updated
2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cognitieve vermoeidheid Myasthenia Gravis

Interventions

None listed

Sponsors

Leids Universitair Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: myasthenia gravis with anti-acetyl choline receptor antibodies

Exclusion criteria

Exclusion criteria: - A medical history of other active auto-immune disorders for which the patient currently receives a medical treatment, such as thyroid disease or rheumatoid arthritis. - A recent medical history of neoplasms. - Substance abuse.

Design outcomes

Primary

MeasureTime frame
The main study parameter is a serum biomarker which correlates with levels of fatigue. We expect this biomarkers to be (partly) influenced by disease severity and treatment. Therefore this study has the option to include a longitudinal design (part II) with data and samples over the course of 6-12 months (2 visits). During this part II of the study fluctuations in fatigue will be related to fluctuations in the previously identified biomarkers.

Secondary

MeasureTime frame
We will collect information on depression scores, age, sex, BMI, medication and degree of physical activity as these factors are associated with fatigue and are likely to influence results.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)